(PharmaNewsWire.Com, October 03, 2017 ) Epilepsy refers to a spectrum of brain disorders manifested by benign to severe, disabling, and life-threatening symptoms. It is caused by factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and trauma during birth. When the underlying cause of the disease is unidentified, as is witnessed in the majority of cases, it is known as idiopathic epilepsy. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures.
Publisher's analysts forecast the epilepsy drugs market in Europe to grow at a CAGR of 3.22% over the period 2014-2019.
The report includes the present scenario and the growth prospects of the epilepsy drugs market in Europe for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of epilepsy.
Publisher's report, Epilepsy Drugs Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
